Evidence map›Paper›PMID 30288597›Full record

ArticleWorld journal of urology2019

Fiducial markers: can the urologist do better?

Catriona Duncan, Daryl Lim Joon, Nathan Lawrentschuk, Trish Jenkins, Michal Schneider, Vincent Khoo, Michael Chao, Marita Lawlor, Rachel O'Meara, Colleen Berry and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Catriona DuncanDepartment of Surgery, Austin Health, University of Melbourne, Melbourne, VIC, Australia.
Daryl Lim JoonDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Nathan LawrentschukDepartment of Surgery, Austin Health, University of Melbourne, Melbourne, VIC, Australia.
Trish JenkinsDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Michal SchneiderRoyal Marsden NHS Foundation Trust, London, UK.
Vincent KhooRoyal Marsden NHS Foundation Trust, London, UK.
Michael ChaoDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Marita LawlorDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Rachel O'MearaDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Colleen BerryDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Angela ViottoDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Kerryn BrownDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Morikatsu WadaDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Farshad ForoudiDepartment of Radiation Oncology, Olivia Newtown-John Cancer Centre, Austin Health, Melbourne, VIC, Australia.
Shomik SenguptaDepartment of Surgery, Austin Health, University of Melbourne, Melbourne, VIC, Australia. Shomik.sengupta@monash.edu.
Austin Health · AUAustin Hospital · AUOlivia Newton-John Cancer Wellness & Research Centre · AURoyal Marsden NHS Foundation Trust · GBEastern Health · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRadiotherapy to the bladder has a risk of toxicity to pelvic structures, which can be reduced by using fiducial markers for targeting. Injectable contrast offers an alternative marker to gold seeds, which may fall out or exacerbate scarring. Combining contrast agents with tissue glue can minimize dispersion through tissue, enhancing its utility. We evaluated combinations of contrast agents and tissue glue using porcine bladder, for feasibility and utility as fiducial markers to aid image-guided radiotherapy.

methodsDifferent contrast agents (Lipiodol ultra or Urografin) were combined with different tissue glues (Histoacryl, Tisseal or Glubran2). The mixtures were endoscopically injected into porcine bladder submucosa to identify the area of interest with multiple fiducial markers. The porcine bladders were imaged within a phantom porcine pelvis using standard radiation therapy imaging modalities. The feasibility as an injectable fiducial marker and visibility of each fiducial marker on imaging were scored as binary outcomes by two proceduralists and two radiation therapists, respectively.

resultsLipiodol-glue combinations were successfully administered as multiple fiducials that were evident on CT and CBCT. Lipiodol with Histoacryl or Glubran2 was visible on kV imaging. The Lipiodol Glubran2 combination was deemed subjectively easiest to use at delivery, and a better fiducial on KV imaging.

conclusionThis study demonstrates the feasibility of mixing contrast medium Lipiodol with Histoacryl or Glubran2 tissue glue, which, injected endoscopically, provides discrete and visible fiducial markers to aid image-guided radiotherapy. Although promising, further study is required to assess the durability of these markers through a course of radiotherapy.

Indexed as

Fiducial MarkersAnimalsCone-Beam Computed TomographyCyanoacrylatesCystoscopyDiatrizoate MeglumineEnbucrilateEthiodized OilFeasibility StudiesFibrin Tissue AdhesiveRadiotherapy, Image-GuidedSwineTissue AdhesivesTomography, X-Ray ComputedUrinary Bladder NeoplasmsCyanoacrylatesDiatrizoate MeglumineEnbucrilateEthiodized OilFibrin Tissue Adhesiveglubran 2Tissue AdhesivesBladder cancerCone beam computed tomographyEndoscopyFiducial markersImage-guided radiotherapyIodized oilProstate cancerTissue glue

Identifiers

PMID30288597
OpenAlexW2895033011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.